A randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation - MMVAR

EBMT - CLWP0 个研究点目标入组 452 人开始时间: 2005年12月13日最近更新: 2017年8月21日

适应症

试验速览

暂无简介。

•-histologically confirmed diagnosis of multiple myeloma with evaluable disease parameters
•-relapsing or having a progressive disease at least one year after an autologous transplantation
•-karnofsky index more than 50%
•-post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
•-written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•-patient with non-secretory MM
•-Creat clearance lower than 30 ml/min, platelets lower then 40000, ANC lower than 1000
•-peripheral neuropathy of grade 2 or more within 14 days before enrollment
•-HIV, hepatitis A,B,C positive
•-female subject pregnant or breast-feeding

发起方

EBMT - CLWP